Among research peptides, few compounds have a published record as concentrated as CJC-1295’s. The CJC-1295 key research findings come from a compact cluster of peer-reviewed studies published mostly in the mid-2000s: the molecule’s design as a long-acting GHRH analogue, animal work demonstrating its activity, and a human trial showing prolonged growth hormone and IGF-1 elevation after a single administration. This roundup collects the CJC-1295 key research findings strictly as published science — what was studied, what was reported, and where the record ends. It is a literature summary for researchers, not a claim about human outcomes, and it ends where the research program itself ended: with clinical development discontinued and the compound handled today as a research chemical.
Research-use-only disclaimer: CJC-1295 is not an FDA-approved drug and is not a medicine. All products on this site are sold strictly for laboratory research use. This article summarizes CJC-1295 key research findings from the published literature. It contains no dosage information, no administration instructions, and no medical advice.
CJC-1295 Key Research Findings at a Glance
For the time-pressed reader, the CJC-1295 key research findings compress into five points. Each is expanded — with its source study — in the sections below.
| Finding | What was reported | Source study |
|---|---|---|
| Long-acting GHRH analogue design | Modified GHRH(1–29) with a Drug Affinity Complex for albumin binding, identified as a long-lasting GRF analogue | Jette et al., Endocrinology, 2005 |
| Prolonged GH elevation in humans | Single administration raised GH 2- to 10-fold, sustained for 6+ days in healthy adults | Teichman et al., J Clin Endocrinol Metab, 2006 |
| Prolonged IGF-1 elevation in humans | IGF-1 rose 1.5- to 3-fold, lasting 9–11 days | Teichman et al., J Clin Endocrinol Metab, 2006 |
| Growth normalization in knockout mice | Once-daily administration normalized growth in GHRH knockout mice | Alba et al., Exp Biol Med, mid-2000s |
| Extended half-life via albumin binding | At least 90% of the compound binds albumin after administration; a half-life on the order of a week was reported | Thorner review, J Neuroendocrinol, 2008 |
How to use this roundup. The CJC-1295 key research findings below are presented chronologically, because the story makes more sense that way: a design problem, a designed molecule, animal validation, then a human trial. Read the timeline first; the finding boxes then give each result its full context.
Timeline: How the CJC-1295 Key Research Findings Accumulated
Early 1980s — GHRH is identified
Growth hormone-releasing hormone, a 44-amino-acid hypothalamic peptide, is characterized as the signal that drives pituitary growth hormone secretion. Native GHRH has a plasma half-life measured in minutes — a fact that would define the entire next chapter of CJC-1295 key research findings: the search for a longer-acting analogue.
Mid-1980s — The degradation problem is mapped
Research shows that native GHRH is rapidly chopped by plasma enzymes into an inactive, N-terminally cleaved product (Frohman and colleagues, Journal of Clinical Investigation, 1986). Any useful analogue would need to survive this enzymatic gauntlet — the design brief CJC-1295 would eventually answer.
2005 — CJC-1295 is identified as a long-lasting GRF analogue
Jette and colleagues (Endocrinology, 2005) describe CJC-1295: a GHRH(1–29) analogue carrying amino acid substitutions for potency and protease resistance, linked through a lysine to a maleimide-based Drug Affinity Complex (DAC). The DAC reacts with the free thiol of albumin’s cysteine-34, so that after administration the compound circulates largely albumin-bound — a reservoir that releases activity over days rather than minutes. This design paper is the foundation of all later CJC-1295 key research findings.
Mid-2000s — Growth normalized in GHRH knockout mice
Alba and colleagues report that once-daily CJC-1295 normalizes growth in mice genetically lacking GHRH (Experimental Biology and Medicine). The result matters because it tests the molecule against a clean causal question — can a long-acting analogue substitute for the missing hormone? — and answers it in the affirmative in that model.
2006 — The human trial: prolonged GH and IGF-1 elevation
Teichman and colleagues (Journal of Clinical Endocrinology & Metabolism, 2006) administer CJC-1295 to healthy adults and report the most-cited of all CJC-1295 key research findings: a single administration produces 2- to 10-fold increases in plasma growth hormone sustained for more than 6 days, and 1.5- to 3-fold increases in IGF-1 lasting 9–11 days, with responses scaling by dose. The effect preserves pulsatile secretion patterns rather than flattening them — a detail the authors highlight.
2008 — Review consolidates the pharmacokinetics
Thorner’s review (Journal of Neuroendocrinology, 2008) summarizes the DAC mechanism: at least 90% of CJC-1295 binds covalently to albumin after administration, with a reported half-life on the order of a week — the pharmacokinetic payoff of the 2005 design.
After the 2000s — Development discontinues
The clinical development program for CJC-1295 was ultimately discontinued, and the compound never advanced to regulatory approval. The CJC-1295 key research findings therefore end as a closed chapter of published science — which is why the compound exists today strictly as a research chemical.
Finding in Focus: The Albumin-Binding Design
The most technically interesting of the CJC-1295 key research findings is the design itself. Most long-acting peptide strategies of the era relied on formulation tricks; CJC-1295 instead outsourced its persistence to the body’s most abundant plasma protein. The maleimide DAC reacts with albumin’s unpaired thiol, effectively hitching the 29-amino-acid peptide to a 66-kilodalton carrier that the kidneys clear slowly. The 2005 Jette paper validated each link in that chain in rats: albumin bioconjugates of the GRF analogue activated the GRF receptor on the anterior pituitary, confirming that the bulky albumin attachment did not destroy receptor activity. For researchers, this finding is a case study in rational peptide engineering — modify for protease resistance, then borrow pharmacokinetics from albumin. Background on the compound is available via the CJC-1295 article on Wikipedia, with the primary literature indexed on PubMed.
DAC vs. no-DAC: a necessary distinction. The published CJC-1295 key research findings above concern the DAC (albumin-binding) form. A separate, shorter-acting analogue — often called modified GRF(1–29) or “CJC-1295 without DAC” — lacks the albumin-binding modification and behaves as a conventional short-acting GHRH analogue. Conflating the two is the most common error in secondary coverage of this literature.
Finding in Focus: The 2006 Human Trial
The Teichman trial is the finding everyone cites, so it deserves a careful reading. Healthy adults received single administrations of CJC-1295, and investigators tracked growth hormone and IGF-1 over the following days. The headline numbers — GH up 2- to 10-fold for 6+ days, IGF-1 up 1.5- to 3-fold for 9–11 days — describe hormone levels, and the authors were explicit that the pattern of secretion remained pulsatile: the pituitary’s natural rhythm of GH pulses continued, with elevated trough levels between pulses, rather than being replaced by a flat pharmacological flood. That distinction is central to how the CJC-1295 key research findings are understood in endocrine terms — prolonged stimulation of the endogenous axis, not replacement of it. Dose-dependency was observed across the tested range. As with all findings here, this describes a published investigational trial, not an approved therapy — CJC-1295 has never been an FDA-approved drug (see the FDA’s drug information pages for what approval means).
Finding in Focus: The Animal Model Work
Before the human trial, the animal studies established that the design worked in living systems. The Jette 2005 rat work showed albumin-bound conjugates activating pituitary GRF receptors — the mechanistic proof of concept. The Alba knockout-mouse study then asked the physiological question: in animals unable to make their own GHRH, could once-daily CJC-1295 restore normal growth? The reported answer was yes. Together, these form the preclinical half of the CJC-1295 key research findings: mechanism confirmed in rats, physiological rescue demonstrated in mice, durability confirmed in humans. It is a tidy translational arc — and a reminder that the compound’s story, while scientifically complete, stopped before any therapeutic application was established.
What the findings don’t show. The CJC-1295 key research findings establish hormone-level effects over days to weeks in controlled studies. They do not establish long-term safety, they do not test clinical outcomes, and the development program that might have answered those questions was discontinued. Absence of evidence is not evidence of safety — it is simply the boundary of the published record, and honest research writing stays inside it.
For researchers placing CJC-1295 in the broader landscape of studied peptides, our site’s research library offers adjacent context: the Semax 10mg and Selank 10mg research listings, our Selank vs Semax research comparison, and the companion research overviews on Semax nasal spray and Selank nasal spray formats. Each stays in the same literature-summary lane as this roundup.
Key Takeaways: CJC-1295 Key Research Findings
The published record is compact and coherent: a 2005 design paper establishing the albumin-binding DAC mechanism, mid-2000s animal work showing receptor activation and growth rescue, and a 2006 human trial reporting multi-day GH and IGF-1 elevation after single administration — followed by discontinuation of clinical development. Those are the CJC-1295 key research findings in full: real, peer-reviewed, bounded, and closed. (Research framing only — a literature summary, not a use recommendation.)
CJC-1295 Key Research Findings: Frequently Asked Questions
Direct answers on the published record for this compound.
What is the most-cited CJC-1295 study?
Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006: a single administration of CJC-1295 in healthy adults produced 2- to 10-fold GH increases sustained for 6+ days and 1.5- to 3-fold IGF-1 increases lasting 9–11 days. It is the centerpiece of the CJC-1295 key research findings and the paper most secondary coverage refers to.
How does CJC-1295 achieve its long-acting profile?
Through its Drug Affinity Complex (DAC): a maleimide-based modification that binds covalently to albumin’s cysteine-34 after administration, so the peptide circulates largely albumin-bound with a reported half-life on the order of a week (Jette et al., 2005; Thorner, 2008). This design finding is one of the CJC-1295 key research findings most cited in peptide-engineering discussions.
Was CJC-1295 ever tested in animals?
Yes. Published work includes rat studies confirming that albumin-bound conjugates activate the pituitary GRF receptor (Jette et al., 2005) and a GHRH knockout mouse study in which once-daily administration normalized growth (Alba et al., mid-2000s).
Is CJC-1295 FDA-approved?
No. CJC-1295 is not an FDA-approved drug, its clinical development program was discontinued, and it is handled today strictly as a research compound. The CJC-1295 key research findings describe investigational science, not an approved medicine.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC form carries the albumin-binding modification responsible for the multi-day profile reported in the literature; the no-DAC form (modified GRF 1–29) lacks it and behaves as a shorter-acting GHRH analogue. The CJC-1295 key research findings summarized here concern the DAC form unless noted.
Where can I read the original papers?
Start with the CJC-1295 overview on Wikipedia for orientation, then trace the primary sources — Jette et al. 2005, Teichman et al. 2006, Thorner 2008 — through PubMed.
Final Notes on the CJC-1295 Key Research Findings
The CJC-1295 key research findings tell a complete, self-contained scientific story: a clear design problem (GHRH’s minutes-long half-life), an elegant engineered solution (albumin binding via DAC), validation across rats, knockout mice, and healthy humans, and then — the part that keeps the story honest — a discontinued development program and no approval. For researchers, that completeness is the value: few compounds offer such a tidy arc from molecule design to human pharmacology in a handful of papers. Read them as published, cite them as published, and let the boundary of the record — where the findings stop — be as instructive as the findings themselves.
